ReviewHuman cell2025
Multi-epitope vaccines: charting a new frontier in monkeypox prevention and control.
Review in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging strategies for monkeypox: antigen and antibody applications in diagnostics, vaccines, and treatments.Military Medical Research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox is a viral zoonotic infection that has emerged as a significant public health threat recently. The world has experienced a global outbreak of the Monkeypox virus (MPXV), with 124,753 confirmed cases in 128 countries and a total of 272 fatalities as of February 13, 2025. This alarming increase in cases demands immediate attention to the underlying causes of the surge. The World Health Organization (WHO) has endorsed the use of the MVA-BN vaccine, which was previously approved for smallpox prevention. However, there are currently no antiviral treatments approved by the FDA for MPXV. In addition, the emergence of mutations in MPXV strains poses challenges for the development and effectiveness of viable vaccines. Developing conventional vaccines is typically expensive, time-consuming, and requires extensive validation processes. Moreover, these vaccines often demonstrate suboptimal efficacy against emerging viral strains. As a response to these challenges, multi-epitope vaccines have gained significant interest for their potential to activate B-cell and T-cell responses, providing prolonged immunological activity against pathogens. These vaccines feature a targeted approach, offering chemical stability, non-infectious properties, rapid and cost-effective production, enhanced safety, and the potential to elicit a robust immune response. Several studies employing immunoinformatics have confirmed the efficacy of multi-epitope vaccines, designed to provide comprehensive immune protection against MPXV. These vaccines promise to deliver a strong immune response, better coverage against various viral strains and variants, and improved stability and effectiveness. In addition, they are expected to be non-allergenic, non-toxic, and highly antigenic. While promising results have been reported regarding the use of these vaccines for monkeypox, further research on their efficacy, delivery systems, and additional preclinical and clinical trials is crucial to maximize their benefits for humanity.
Indexed as
Identifiers
40632349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.